COVID-19, Antiphospholipid Antibodies, and Catastrophic Antiphospholipid Syndrome: A Possible Association?

Area of Science:

• Internal Medicine
• Hematology
• Infectious Diseases

Background:

• The 2019 novel coronavirus (COVID-19) pandemic has accelerated research into its complications.
• Abnormal coagulation and high thrombosis prevalence are observed in COVID-19 patients.
• Anti-phospholipid antibodies (aPL) are investigated as a potential mechanism for COVID-19-associated thrombosis.

Purpose of the Study:

• To explore the potential association between COVID-19, anti-phospholipid antibodies (aPL), and thrombotic events.
• To investigate the possibility of SARS-CoV-2 inducing catastrophic anti-phospholipid syndrome (CAPS).
• To highlight the need for high-quality studies on aPL's role in COVID-19 thrombosis and thromboprophylaxis.

Main Methods:

• Review of case reports and cross-sectional studies on COVID-19 and coagulation.
• Analysis of the potential pathogenic role of anti-phospholipid antibodies (aPL) in COVID-19 thrombosis.
• Exploration of the link between viral infections and catastrophic anti-phospholipid syndrome (CAPS).

Main Results:

• A high prevalence of thrombosis is noted in COVID-19 patients.
• The presence of aPL in COVID-19 patients is rare, and their association with thrombosis remains debated.
• No clear association between COVID-19 and catastrophic anti-phospholipid syndrome (CAPS) has been established.

Conclusions:

• Further high-quality research is essential to elucidate the pathogenic role of aPL in COVID-19-associated thrombosis.
• The potential for SARS-CoV-2 to induce CAPS warrants investigation.
• Understanding these mechanisms is crucial for developing effective thromboprophylaxis strategies for COVID-19 patients.